Fosun Peak enters vaccine field

Fosun Pharma will enter the vaccine field with higher industry barriers by holding the Dalian Accor Peak Biopharmaceutical Co., Ltd. Fosun Pharmaceutical wholly-owned subsidiary Fosun Industrial (Hong Kong) Co., Ltd., Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. was on January 27 with the existing shareholders of the company Accor Peak Biotechnology Holdings Limited, Beijing and Xin Bo Industry Consulting Co., Ltd. signed the "Equity transfer Agreement", Fosun Industrial intends to contribute 666 million yuan to be held by the Yali Peak holdings of Dalian ya Li Peak 74% of the equity, industrial development to invest 9 million yuan and Xin Bo industry held by the Dalian Ya Li Peak 1% of the equity. Trading pricing includes expectations of the future of the rabies vaccine business that is being approved by Dalian's Accor Peak.　　Up to now, the Dalian ya Li Peak Rabies vaccine products pending approval of the National Drug Administration. After the completion of the above transaction, Dalian Accor Peak will be included in the scope of the combined report of Fosun Medicine. Fosun Medicine will achieve the domestic excellent vaccine research and development and production enterprises in Dalian Accor Peak Holding, so into a high industry barriers in the field of vaccines, product structure will be further enriched and optimized, comprehensive competitiveness is expected to further upgrade.　　However, the above transaction needs to obtain the approval of the relevant commercial authorities. Dalian ya Li Peak is one of the 11 domestic influenza vaccine manufacturers and 9 swine flu vaccine manufacturers, has been put into production products have influenza virus cracked vaccine, influenza A (H1N1) vaccine. Dalian ya Li Peak in the field of influenza and rabies vaccine technology is leading position. As of November 30, 2010, Dalian Accor Peak audited total assets of 150 million yuan, the owner's equity of 96.66 million yuan, the total liability of 53.23 million yuan.　　2010 1 to November, Dalian ya Li Peak to achieve operating income of 98.71 million yuan, to achieve a net profit of 50.89 million yuan. In addition, Fosun Pharmaceutical disclosed that the company's 2010 annual net profit of 850 million to 950 million yuan, 60% to 65% lower than 2009, the specific data will be disclosed in the 2010 report.　　The decline in performance was due to a larger base in the previous year. In September 2009, Fosun Pharma's investment in the Chinese Medicine Holdings Co., Ltd. was listed on the Stock exchange of Hong Kong, Fosun Pharmaceutical through the Chinese Medicine Industry Investment Co., Ltd. to hold the corresponding increase in the rights of Chinese Medicine, the one-time impact of the 2009 net profit of Fosun is about 1.968 billion yuan.